secwatch.observer — SEC 8-K summary
======================================

Issuer:     CYTOKINETICS INC (CYTK)
CIK:        0001061983
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0000950170-23-017822
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytokinetics Q1 net loss widens to $131.3M; omecamtiv CRL; cuts spend 10%
-------------------------------------------------------------------------

- Net loss of $131.3M ($1.38/shr) vs $89.4M ($1.05) in Q1 2022; revenue $4.6M (up from $1.1M).
- Cash $704.4M; plans to reduce 2023 spending >10% to maintain >2 years cash runway.
- FDA issued Complete Response Letter for omecamtiv mecarbil NDA; EMA MAA review ongoing.
- SEQUOIA-HCM enrollment nearly complete; top-line results expected Q4 2023.
- COURAGE-ALS met futility criteria; company discontinuing reldesemtiv treatment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/0000950170-23-017822-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1061983/000095017023017822/cytk-20230504.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-017822

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer